A FLOP is a single floating‑point operation, meaning one arithmetic calculation (add, subtract, multiply, or divide) on ...

And then it got me.” A handful of decades and an MIT physics doctorate later, Tan is the chief science officer (CSO) of ...

Encouraged by these results, Dudin, Dey, Guichard, and Hamel launched a close collaboration. Three years later, their work has produced near-encyclopedic insight into hundreds of protist species and ...

I have zero programming skills. But after a few minor setbacks, I was able to build a custom website in no time.

The 2026 ACS president will spend the society's 150th anniversary focusing on growing ACS's platform and engaging its members ...

The topic of AI and its implications for orthopedic surgeons became of high personal importance when Bill Gates predicted that AI would replace physicians and others within the next decade. As an ...

Recently, micro/nanosatellites have become a significant trend in space with the rapid development of space technology, ...

Structure’s aleniglipron elicited over 11% weight loss in a Phase II trial, sending the biotech’s stock up nearly 103% as markets closed on Monday. Structure Therapeutics’ investigational oral GLP-1 ...

Structure Therapeutics Inc. earns a Strong Buy rating following robust phase 2b data for oral GLP-1R agonist Aleniglipron in obesity. Aleniglipron achieved placebo-adjusted weight loss up to -15.3% at ...

Placebo-adjusted mean weight loss of 11.3% (27.3 lbs) with 120 mg dose in the 36-week Phase 2b ACCESS study with a 10.4% adverse event-related treatment discontinuation Placebo-adjusted mean weight ...

SAN FRANCISCO, Dec. 08, 2025 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for ...

SAN FRANCISCO, Dec. 07, 2025 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for ...